HIV p24

HIV p24 Antigen ELISA References

Journal references for ZMC’s HIV p24 Antigen ELISA Kit

Baba M, Takashima K, Miyake H, et al. TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans. Antimicrob Agents Chemother. 2005; 49 (11): 4584-4591.

Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral Gene Transfer of Rpe65 Rescues Survival and Function of Cones in a Mouse Model of Leber Congenital Amaurosis. PLoS Med. 2006; 3 (10): e347.

Blancou P, Evans DT, Desrosiers RC. PRA1 co-localizes with envelope but does not influence primate lentivirus production, infectivity or envelope incorporation. Journal of General Virology. 2005; 86: 1785-1790.

Caceda R, Kinkead B, Owens M, et al. Virally Mediated Increased Neurotensin 1 Receptor in the Nucleus Accumbens Decreases Behavioral Effects of Mesolimbic System Activation. The Journal of Neuroscience. 2005; 25 (50): 11748-11756.

Emori Y, Ikeda T, Ohashi T, et al. Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virology. 2004; 85: 2603-2613.

Fang J, Kubota S, Pomerantz RJ. A Trans-Dominant Negative HIV Type 1 Rev with Intact Domains of NLS/NOS and NES. AIDS Research and Human Retroviruses. 2002; 18 (10): 705-709.

Finnegan CM, Rawat SS, Puri A, et al. Ceramide, a target for antiretroviral therapy. Proc Natl Acad Sci U S A. 2004; 101 (43): 15452-15457.

Forthal DN, Landucci G, Daar ES. Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells. J Virol. 2001; 75 (15): 6953-6961.

Forthal DN, Landucci G, Phan TB, et al. Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. J Virol. 2005; 79 (4): 2042-2049

Hamer DH, Bocklandt S, McHugh L, et al. Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication. J Virol. 2003; 77 (19): 10227-10236.

Ikeda T, Nishitsuji H, Zhou X, et al. Evaluation of the Functional Involvement of Human Immunodeficiency Virus Type 1 Integrase in Nuclear Import of Viral cDNA during Acute Infection. J Virol . 2004; 78 (21): 11563-11573.

Jiang YH, Emau P, Cairns S, et al. SPL7013 Gel as a Topical Microbicide for Prevention of Vaginal Transmission of SHIV89.6P in Macaques. AIDS Research and Human Retroviruses. 2005; 21 (3): 207-213.

Kamada K, Igarashi T, Martin MA, et al. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc Natl Acad Sci U S A. 2006; 103 (45): 16959-16964.

Kameoka M, Nukuzuma S, Itaya A, et al. RNA Interference Directed against Poly(ADP-Ribose) Polymerase 1 Efficiently Suppresses Human Immunodeficiency Virus Type 1 Replication in Human Cells. J Virol. 2004; 78 (16): 8931-8934.

Kawano Y, Yoshida T, Hieda K, et al. A Lentiviral cDNA Library Employing Lambda Recombination Used To Clone an Inhibitor of Human Immunodeficiency Virus Type 1-Induced Cell Death. J Virol. 2004; 78 (20): 11352-11359.

Kino T, Gragerov A, Slobodskaya O, et al. Human Immunodeficiency Virus Type 1 (HIV-1) Accessory Protein Vpr Induces Transcription of the HIV-1 and Glucocorticoid-Responsive Promoters by Binding Directly to p300/CBP Coactivators. J Virol. 2002; 76 (19): 9724-9734.

Kobayashi M, Takaori-Kondo A, Shindo K, et al. APOBEC3G Targets Specific Virus Species. J Virol. 2004; 78 (15): 8238-8244.

Komoto S, Tsuji S, Ibrahim MS, et al. The Vpu Protein of Human Immunodeficiency Virus Type 1 Plays a Protective Role against Virus-Induced Apoptosis in Primary CD4 + T Lymphocytes. J Virol. 2003; 77 (19): 10304-10313.

Lawrence DMP, Durham LC, Schwartz L, et al. Human Immunodeficiency Virus Type 1 Infection of Human Brain-Derived Progenitor Cells. J Virol. 2004; 78 (14): 7319-7328.

Marodon G, Klatzmann D. In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectors. BMC Immunology. 2004; 5: 18.

McGettigan JP, Naper K, Orenstein J, et al. Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome. J Virol. 2003; 77 (20): 10889-10899.

McGettigan JP, Pomerantz RJ, Siler CA, et al. Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic. J Virol. 2003; 77 (1): 237-244.

McGettigan JP, Sarma S, Orenstein JM, et al. Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine Vector. J Virol. 2001; 75 (18): 8724-8732.

Miyauchi K, Komano J, Yokomaku Y, et al. Role of the Specific Amino Acid Sequence of the Membrane-Spanning Domain of Human Immunodeficiency Virus Type 1 in Membrane Fusion. J Virol. 2005; 79 (8): 4720-4729.

Nishikawa M, Takashima K, Nishi T, et al. Analysis of Binding Sites for the New Small-Molecule CCR5 Antagonist TAK-220 on Human CCR5. Antimicrob Agents Chemother.2005; 49 (11): 4708-4715.

Nishitsuji H, Kohara M, Kannagi M, et al. Effective Suppression of Human Immunodeficiency Virus Type 1 through a Combination of Short- or Long-Hairpin RNAs Targeting Essential Sequences for Retroviral Integration. J Virol. 2006; 80 (15): 7658-7666.

Nitanda T, Wang X, Kumamoto H, et al. Anti-Human Immunodeficiency Virus Type 1 Activity and Resistance Profile of 2′,3′-Didehydro-3′-Deoxy-4′-Ethynylthymidine In Vitro.Antimicrob Agents Chemother. 2005; 49 (8): 3355-3360.

Oruetxebarria I, Venturini F, Kekarainen, et al. p 16INK4a Is Required for hSNF5 Chromatin Remodeler-induced Cellular Senescence in Malignant Rhabdoid Tumor Cells. J. Biol. Chem. 2004; 279 (5): 3807-3816.

Sakuragi J, Iwamoto A, Shioda T. Dissociation of Genome Dimerization from Packaging Functions and Virion Maturation of Human Immunodeficiency Virus Type 1. Journal of Virology. 2002; 76 (3): 959-967.

Sakuragi J, Ueda S, Iwamoto A, et al. Possible Role of Dimerization in Human Immunodeficiency Virus Type 1 Genome RNA Packaging. J Virol. 2003; 77 (7): 4060-4069.

Shoya Y, Tokunaga K, Sawa H, et al. Human topoisomerase I promotes HIV-1 proviral DNA synthesis: Implications for the species specificity and cellular tropism of HIV-1 infection. PNAS. 2003; 100 (14): 8442-8447.

Smulevitch S, Michalowski D, Zolotukhin AS, et al. Structural and Functional Analysis of the RNA Transport Element, a Member of an Extensive Family Present in the Mouse Genome. J Virol. 2005; 79 (4): 2356-2365.

Takashima K, Miyake H, Furuta RA, et al. Inhibitory Effects of Small-Molecule CCR5 Antagonists on Human Immunodeficiency Virus Type 1 Envelope-Mediated Membrane Fusion and Viral Replication. Antimicrob Agents Chemother. 2001; 45 (12): 3538-3543.

Takashima K, Miyake H, Kanzaki N, et al. Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist. Antimicrob Agents Chemother. 2005; 49 (8): 3474-3482.

Tomiyama H, Akari H, Adachi A, et al. Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8 + T-Cell Cytolytic Activity and Cytokine Production. J Virol. 2002; 76 (15): 7535-7543.

Trushin SA, Bren GD, Asin S, et al. Human Immunodeficiency Virus Reactivation by Phorbol Esters or T-Cell Receptor Ligation Requires both PKCα and PKCθ. J Virol. 2005; 79 (15): 9821-9830.

Yokomaku Y, Miura H, Tomiyama H, et al. Impaired Processing and Presentation of Cytotoxic-T-Lymphocyte (CTL) Epitopes Are Major Escape Mechanisms from CTL Immune Pressure in Human Immunodeficiency Virus Type 1 Infection. J Virol. 2004; 78 (3): 1324-1332.

Yonezawa A, Morita R, Takaori-Kondo A, et al. Natural Alpha Interferon-Producing Cells Respond to Human Immunodeficiency Virus Type 1 with Alpha Interferon Production and Maturation into Dendritic Cells. J Virol. 2003; 77 (6): 3777-3784.

Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2002; 99 (10): 7015-7020.

Zhang C, Chen Y, Ben K. An improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasma. BMC Infect Dis. 2003; 3: 30.

Zhang XY, La Russa VF, Jakob Reiser J. Transduction of Bone-Marrow-Derived Mesenchymal Stem Cells by Using Lentivirus Vectors Pseudotyped with Modified RD114 Envelope Glycoproteins. J Virol. 2004; 78 (3): 1219-1229.